nemonoxacin: has antibacterial activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 11993740 |
CHEMBL ID | 1213456 |
CHEBI ID | 136053 |
SCHEMBL ID | 1006373 |
MeSH ID | M0539102 |
Synonym |
---|
CHEMBL1213456 |
CHEBI:136053 |
nemonoxacin |
tg-873870 |
p94l0pvo94 , |
tg873870 |
tg 873870 |
nemonoxacin [inn] |
378746-64-6 |
unii-p94l0pvo94 |
SCHEMBL1006373 |
3-quinolinecarboxylic acid, 7-((3s,5s)-3-amino-5-methyl-1-piperidinyl)-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo- |
nemonoxacin [who-dd] |
7-[(3s,5s)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4- oxo-1,4-dihydroquinoline-3-carboxylic acid |
7-[(3s,5s)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid |
7-((3s,5s)-3-amino-5-methylpiperidin-1-yl)-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid |
DB06600 |
Q15425793 |
gtpl10836 |
7-[(3s,5s)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxoquinoline-3-carboxylic acid |
MS-25985 |
DTXSID10958907 |
TQP0855 |
HY-14956 |
CS-0003656 |
STARBLD0028467 |
Nemonoxacin (TG-873870) is a novel nonfluorinated quinolone with broad-spectrum activities against Gram-positive and Gram-negative aerobic, anaerobic, and atypical pathogens. It has strong antibacterial efficacy, but data of its effect on acute exacerbations of chronic obstructive pulmonary disease (AECOPD) is rare.
Excerpt | Reference | Relevance |
---|---|---|
"Nemonoxacin (TG-873870) is a novel nonfluorinated quinolone with potent broad-spectrum activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus, penicillin- and quinolone-resistant Streptococcus pneumoniae, and vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. " | ( Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. Ajayi, F; Aronstein, WS; Chang, LW; Chung, DT; Hsu, CH; Kuzmak, B; Lin, L; Lyon, RA; Tsai, CY, 2010) | 2.03 |
"Nemonoxacin (TG-873870) is a novel nonfluorinated quinolone with broad-spectrum activities against Gram-positive and Gram-negative aerobic, anaerobic, and atypical pathogens, as well as against methicillin-resistant Staphylococcus aureus, vancomycin-resistant S. " | ( Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. Chang, LW; Chang, YT; Chen, SJ; Chiu, KM; Chung, DT; Hsu, CH; Hsu, MC; King, CH; Tan, HC; Tsai, CY, 2010) | 2.04 |
"Nemonoxacin is a novel non-fluorinated quinolone with strong antibacterial efficacy, but data of its effect on acute exacerbations of chronic obstructive pulmonary disease (AECOPD) is rare. " | ( Nemonoxacin achieved a better symptomatic improvement and a prolonged interval to next exacerbation than moxifloxacin for outpatients with acute exacerbations of chronic obstructive pulmonary disease. Chen, Y; Li, Z; Meng, W; Xiong, R; Zeng, H; Zhao, Z, 2023) | 3.8 |
"Nemonoxacin is a nonfluorinated quinolone with good bactericidal effects against quinolone-resistant Gram-positive microorganisms. " | ( Selected Mutations by Nemonoxacin and Fluoroquinolone Exposure Among Relevant Gram-Positive Bacterial Strains in Taiwan. Chang, LW; Cheng, A; Hsu, MC; Sheng, WH; Tai, HM; Yang, JJ, 2020) | 2.32 |
"Nemonoxacin is a novel non-fluorinated quinolone. " | ( Nemonoxacin Has Immunoprotective Effects on Reducing Mortality in Lipopolysaccharide-Induced Mouse Sepsis Model. Chen, N; Feng, M; Guo, B; Huang, J; Li, X; Lin, D; Zhao, X; Zou, J, 2020) | 3.44 |
"Nemonoxacin is a novel nonfluorinated quinolone with excellent in vitro activity against most pathogens in community-acquired pneumonia (CAP), especially Gram-positive isolates. " | ( Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial. Cao, Z; Chang, L; Cheng, SL; Lv, Y; Ma, Z; Mo, B; Sun, S; Tong, Z; Wu, J; Wu, R; Yang, Y; Yuan, J; Zhang, Y; Zhu, D, 2019) | 2.25 |
"Nemonoxacin is a novel C-8-methoxy nonfluorinated quinolone that has been approved for the treatment of community-acquired pneumonia (CAP) in adults. " | ( Population Pharmacokinetics Study of Nemonoxacin Among Chinese Patients With Moderate Hepatic Impairment. Chen, Y; Guo, B; Kang, Y; Li, Y; Wang, K; Wu, J; Xu, F; Yu, J; Zhang, J; Zhang, Y, 2019) | 2.23 |
"Nemonoxacin is a novel C-8-methoxy nonfluorinated quinolone with remarkably enhanced in vitro activity against a wide variety of clinically relevant pathogens, especially gram-positive bacteria, including multidrug-resistant Streptococcus pneumoniae and methicillin-resistant Staphylococcus aureus. " | ( Review of nemonoxacin with special focus on clinical development. Huang, H; Qin, X, 2014) | 2.25 |
"Nemonoxacin (TG-873870) is a novel nonfluorinated quinolone with potent broad-spectrum activity against Gram-positive, Gram-negative, and atypical pathogens, including vancomycin-nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA), quinolone-resistant MRSA, quinolone-resistant Streptococcus pneumoniae, penicillin-resistant S. " | ( Safety, tolerability, and pharmacokinetics of intravenous nemonoxacin in healthy chinese volunteers. Cao, GY; Chen, YC; Guo, BN; Shi, YG; Wu, JF; Wu, XJ; Yu, JC; Zhang, J; Zhang, YY, 2014) | 2.09 |
"Nemonoxacin (TG-873870) is a novel C-8-methoxy nonfluorinated quinolone with higher activity than ciprofloxacin, levofloxacin and moxifloxacin against Gram-positive pathogens including methicillin-susceptible or methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae with various resistant phenotypes. " | ( A liquid chromatography-tandem mass spectrometry assay for the determination of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, in human plasma and urine and its application to a single-dose pharmacokinetic study in healthy Chinese volunteers. Guo, B; Shi, Y; Tsai, CY; Wu, X; Yu, J; Zhang, J, 2012) | 2.05 |
Excerpt | Reference | Relevance |
---|---|---|
"Nemonoxacin has a sound PK profile in healthy volunteers." | ( Review of nemonoxacin with special focus on clinical development. Huang, H; Qin, X, 2014) | 1.53 |
"Oral nemonoxacin has been approved in Taiwan for the treatment of CAP in adults." | ( Nemonoxacin: first global approval. Poole, RM, 2014) | 2.3 |
Excerpt | Reference | Relevance |
---|---|---|
"Nemonoxacin showed lower MICs against clinical C." | ( The potential role of nemonoxacin for treatment of common infections. Chen, YH; Hsueh, PR; Huang, CH; Lai, CC, 2015) | 1.45 |
Nemonoxacin was generally safe and well tolerated, with no significant changes in the clinical laboratory tests or electrocardiograms. The incidence of adverse events (AEs) was comparable between nemonxacin (33%) and levofloxacins (33%).
The method was successfully applied to a pharmacokinetic study enrolling 12 healthy Chinese volunteers. The peak time and elimination half-life of nemonoxacin were 1 to 2 h and 9 to 16 h, respectively. This first-in-human study was aimed at assessing the safety, tolerability, and pharmacokinetics properties of intravenous nemon Oxacin.
Excerpt | Reference | Relevance |
---|---|---|
" The validated methods were successfully applied to an absolute bioavailability clinical study of nemonoxacin malate capsule." | ( Determination of a novel nonfluorinated quinolone, nemonoxacin, in human feces and its glucuronide conjugate in human urine and feces by high-performance liquid chromatography-triple quadrupole mass spectrometry. Cao, G; Guo, B; He, G; Shi, Y; Tsai, CY; Wu, X; Yu, J; Zhang, J, 2015) | 0.89 |
Nemonoxacin 0.5-750 mg exhibited a linear dose-response relationship between the AUC0-72 h and A UC0-∞. PPK/pharmacodynamic modelling and simulation of 4 dosage regimens found that nemonxacin was safe to use once daily.
Class | Description |
---|---|
quinolines | A class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID495544 | Toxicity in human assessed as occurrence of somnolence at 1000 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID570925 | Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 64 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495607 | Renal clearance in human at 500 mg/kg, po measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID571353 | Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID570928 | Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571363 | Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of >=512 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID570683 | Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.015 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495476 | Clearance in healthy human assessed as recovery of unchanged drug in urine at 125 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID570685 | Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571359 | Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 32 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571361 | Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 128 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID570696 | Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.015 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495433 | Cmax in healthy human at 50 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495578 | Terminal half life in human at 75 mg/kg, po measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495537 | Toxicity in human assessed as occurrence of diarrhea at 1000 mgkg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495787 | Cmax in human at 500 mg/kg, po measured on day 16 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID570668 | Antibacterial activity against Staphylococcus aureus by CLSI M7-A7 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495482 | Antimicrobial activity against penicillin-sensitive Streptococcus pneumoniae | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495388 | Toxicity in healthy human assessed as occurrence of headache at 1000 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID570701 | Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID570708 | Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 64 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495387 | Toxicity in healthy human assessed as occurrence of headache at 500 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495424 | Toxicity in healthy human assessed as occurrence of ear pain at 1500 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID570694 | Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 32 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495463 | Clearance in healthy human at 250 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID570664 | Antibacterial activity against methicillin-susceptible Staphylococcus aureus by CLSI M7-A7 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495472 | Renal clearance in healthy human at 1000 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID570665 | Antibacterial activity against methicillin-resistant Staphylococcus aureus by CLSI M7-A7 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495494 | Ratio of fAUC to MIC90 for methicillin-resistant Staphylococcus aureus | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID570675 | Antibacterial activity against Stenotrophomonas maltophilia by CLSI M7-A7 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571381 | Antibacterial activity against Klebsiella oxytoca assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571382 | Antibacterial activity against Klebsiella oxytoca assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID570687 | Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495533 | Toxicity in human assessed as occurrence of pruritus at 750 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495577 | Terminal half life in human at 750 mg/kg, po measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID570917 | Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID570901 | Antibacterial activity against non-levofloxacin susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID570702 | Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495611 | Renal clearance in human at 1000 mg/kg, po measured on day 1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID571366 | Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495465 | Clearance in healthy human at 1000 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571141 | Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495442 | Tmax in healthy human at 250 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID570688 | Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571358 | Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495455 | Terminal volume of distribution in healthy human at 125 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495584 | Clearance in human assessed as compound recovered in urine at 250 mg/kg, po measured on day 1 up to 24 hrs post dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID570909 | Antibacterial activity against community-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495471 | Renal clearance in healthy human at 500 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495569 | AUC (0 to 24 hrs) in human at 75 mg/kg, po measured on day 1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495610 | Renal clearance in human at 750mg/kg, po measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495528 | Toxicity in human assessed as occurrence of abdominal pain at 750 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495621 | AUC (0 to 24 hrs) in human at 500 mg/kg, po measured on day 1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID571848 | Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of >=512 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495591 | Clearance in human assessed as compound recovered in urine at 1000 mg/kg, po measured on day 1 up to 24 hrs post dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID571869 | Antibacterial activity against Stenotrophomonas maltophilia assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495419 | Toxicity in healthy human assessed as occurrence of ear pain at 50 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495623 | AUC(0 to last) in human at 500 mg/kg, po measured on day 1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495572 | AUC (0 to last) in human at 250 mg/kg, po measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495499 | Ratio of fCmax to MIC90 for ciprofloxacin-resistant Streptococcus pneumoniae | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495403 | Toxicity in healthy human assessed as occurrence of abdominal pain at 1500 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID570706 | Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571881 | Antibacterial activity against Acinetobacter baumannii assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495556 | Tmax in human at 75 mg/kg, po measured on day 1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID570918 | Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495604 | Renal clearance in human at 250 mg/kg, po measured on day 1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID570898 | Antibacterial activity against non-levofloxacin susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID570920 | Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495429 | AUC (0 to infinity) in healthy human at 500 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID570921 | Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495583 | Clearance in human assessed as compound recovered in urine at 75 mg/kg, po measured on day 10 up to 24 hrs post dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495441 | Tmax in healthy human at 125 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID570900 | Antibacterial activity against non-levofloxacin susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495600 | Oral clearance in human at 1000 mg/kg measured on day 1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495573 | AUC (0 to 24 hrs) in human at 750 mg/kg, po measured on day 1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495428 | AUC (0 to infinity) in healthy human at 250 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571878 | Antibacterial activity against Acinetobacter baumannii assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495647 | Toxicity in healthy human assessed as occurrence of erythema at 125 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID570705 | Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495530 | Toxicity in human assessed as occurrence of pruritus at 75 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID571843 | Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495480 | Clearance in healthy human assessed as recovery of unchanged drug in urine at 1500 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495439 | Tmax in healthy human at 25 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495567 | Tmax in human at 1000 mg/kg, po measured on day 1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID571850 | Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571847 | Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 32 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID570899 | Antibacterial activity against non-levofloxacin susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495532 | Toxicity in human assessed as occurrence of pruritus at 500 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495400 | Toxicity in healthy human assessed as occurrence of abdominal pain at 250 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571345 | Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 32 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571844 | Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495401 | Toxicity in healthy human assessed as occurrence of abdominal pain at 500 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495421 | Toxicity in healthy human assessed as occurrence of ear pain at 250 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID570896 | Antibacterial activity against non-levofloxacin susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495627 | Plasma protein binding in human | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495602 | Renal clearance in human at 75 mg/kg, po measured on day 1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495523 | Toxicity in human assessed as occurrence of rashes at 75 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID571867 | Antibacterial activity against Stenotrophomonas maltophilia assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID570697 | Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.03 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID570927 | Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.03 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495431 | AUC (0 to infinity) in healthy human at 1500 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495538 | Toxicity in human assessed as occurrence of pollakiuria at 75 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID571842 | Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID570672 | Antibacterial activity against Enterococcus faecium by CLSI M7-A7 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495366 | Toxicity in healthy human assessed as occurrence of contact dermatitis at 25 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495481 | Antimicrobial activity against Streptococcus pneumoniae | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571841 | Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495405 | Toxicity in healthy human assessed as occurrence of pustular rashes at 50 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495468 | Renal clearance in healthy human at 50 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495617 | AUC (0 to 24 hrs) in human at 750 mg/kg, po measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID570667 | Antibacterial activity against community-associated methicillin-resistant Staphylococcus aureus by CLSI M7-A7 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571130 | Antibacterial activity against penicillin-resistant Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.015 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495413 | Toxicity in healthy human assessed as occurrence of nausea at 125 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495497 | Ratio of fCmax to MIC90 for penicillin-intermediate Streptococcus pneumoniae | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495727 | Clearance in healthy human assessed as recovery of unchanged drug in urine at 25 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID570690 | Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495615 | AUC (0 to 24 hrs) in human at 250 mg/kg, po measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID571365 | Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.03 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID570916 | Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495450 | Terminal phase elimination half-life in healthy human at 500 mg/kg, po administered single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID570671 | Antibacterial activity against Enterococcus faecalis by CLSI M7-A7 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571380 | Antibacterial activity against Klebsiella oxytoca assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571342 | Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495483 | Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495469 | Renal clearance in healthy human at 125 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495380 | Toxicity in healthy human assessed as occurrence of erythema at 500 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495460 | Clearance in healthy human at 25 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495399 | Toxicity in healthy human assessed as occurrence of abdominal pain at 125 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495566 | Tmax in human at 750 mg/kg, po measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID570923 | Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495500 | Ratio of fCmax to MIC90 for methicillin-sensitive Staphylococcus aureus | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID570932 | Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495599 | Oral clearance in human at 500 mg/kg measured on day 16 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID571118 | Antibacterial activity against Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.015 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495601 | Oral clearance in human at 1000 mg/kg measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495521 | Toxicity in human assessed as occurrence of dermatitis at 500 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495575 | AUC (0 to 24 hrs) in human at 1000 mg/kg, po measured on day 1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495394 | Toxicity in healthy human assessed as occurrence of oral hypoesthesia at 500 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495432 | Cmax in healthy human at 25 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495410 | Toxicity in healthy human assessed as occurrence of pustular rashes at 1500 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495570 | AUC (0 to last) in human at 75 mg/kg, po measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495435 | Cmax in healthy human at 250 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495488 | Ratio of fAUC to MIC90 for Streptococcus pneumoniae | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495559 | AUC (0 to 24 hrs)in human at 500 mg/kg, po measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID571853 | Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571836 | Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID570929 | Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495589 | Clearance in human assessed as compound recovered in urine at 750 mg/kg, po measured on day 1 up to 24 hrs post dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495562 | Tmax in human at 500 mg/kg, po measured on day 1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID571862 | Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of >=512 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495588 | Clearance in human assessed as compound recovered in urine at 500 mg/kg, po measured on day 16 up to 24 hrs post dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID571852 | Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495526 | Toxicity in human assessed as occurrence of abdominal pain at 250 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495375 | Toxicity in healthy human assessed as occurrence of pruritus at 1500 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495603 | Renal clearance in human at 75 mg/kg, po measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495364 | Toxicity in healthy human assessed as occurrence of contact dermatitis at 125 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495495 | Ratio of fCmax to MIC90 for Streptococcus pneumoniae | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571860 | Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 128 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495367 | Toxicity in healthy human assessed as occurrence of contact dermatitis at 1000 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495557 | Tmax in human at 250 mg/kg, po measured on day 1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495417 | Toxicity in healthy human assessed as occurrence of nausea at 1500 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID570887 | Antibacterial activity against Levofloxacin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.015 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495420 | Toxicity in healthy human assessed as occurrence of ear pain at 125 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID570926 | Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.015 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495436 | Cmax in healthy human at 500 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495427 | AUC (0 to infinity) in healthy human at 125 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495440 | Tmax in healthy human at 50 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571348 | Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of <=0.015 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571338 | Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID570676 | Antibacterial activity against Acinetobacter baumannii by CLSI M7-A7 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571370 | Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495386 | Toxicity in healthy human assessed as occurrence of headache at 250 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571343 | Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495371 | Toxicity in healthy human assessed as occurrence of pruritus at 125 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495408 | Toxicity in healthy human assessed as occurrence of pustular rashes at 500 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495586 | Clearance in human assessed as compound recovered in urine at 500 mg/kg, po measured on day 1 up to 24 hrs post dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495498 | Ratio of fCmax to MIC90 for penicillin-resistant Streptococcus pneumoniae | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495598 | Oral clearance in human at 500 mg/kg measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495594 | Oral clearance in human at 75 mg/kg measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495383 | Toxicity in healthy human assessed as occurrence of headache at 25 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495574 | AUC (0 to last) in human at 750 mg/kg, po measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495612 | Renal clearance in human at 1000 mg/kg, po measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495529 | Toxicity in human assessed as occurrence of abdominal pain at 1000 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495553 | Cmax in human at 750 mg/kg, po measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495422 | Toxicity in healthy human assessed as occurrence of ear pain at 500 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495585 | Clearance in human assessed as compound recovered in urine at 250 mg/kg, po measured on day 10 up to 24 hrs post dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495605 | Renal clearance in human at 250 mg/kg, po measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495596 | Oral clearance in human at 250 mg/kg measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID570700 | Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571105 | Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID570905 | Antibacterial activity against community-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.015 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495437 | Cmax in healthy human at 1000 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495398 | Toxicity in healthy human assessed as occurrence of abdominal pain at 50 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495625 | Oral clearance in human at 750 mg/kg measured on day 1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID571347 | Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 128 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID570906 | Antibacterial activity against community-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571351 | Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495501 | Ratio of fCmax to MIC90 for methicillin-resistant Staphylococcus aureus | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495425 | AUC (0 to infinity) in healthy human at 25 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID570689 | Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495535 | Toxicity in human assessed as occurrence of diarrhea at 500 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495473 | Renal clearance in healthy human at 1500 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495389 | Toxicity in healthy human assessed as occurrence of headache at 1500 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495619 | AUC (0 to 24 hrs) in human at 1000 mg/kg, po measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495489 | Ratio of fAUC to MIC90 for Penicillin-sensitive Streptococcus pneumoniae | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495396 | Toxicity in healthy human assessed as occurrence of oral hypoesthesia at 1500 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495434 | Cmax in healthy human at 125 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571120 | Antibacterial activity against Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571872 | Antibacterial activity against Stenotrophomonas maltophilia assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 32 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495393 | Toxicity in healthy human assessed as occurrence of oral hypoesthesia at 250 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495395 | Toxicity in healthy human assessed as occurrence of oral hypoesthesia at 1000 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID570684 | Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.03 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495444 | Tmax in healthy human at 1000 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571121 | Antibacterial activity against Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495458 | Terminal volume of distribution in healthy human at 1000 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495426 | AUC (0 to infinity) in healthy human at 50 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571385 | Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495614 | AUC (0 to last) in human at 75 mg/kg, po measured on day 1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID571576 | Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495576 | AUC (0 to last) in human at 1000 mg/kg, po measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495449 | Terminal phase elimination half-life in healthy human at 250 mg/kg, po administered single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495543 | Toxicity in human assessed as occurrence of somnolence at 750 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID570904 | Antibacterial activity against non-levofloxacin susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 64 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495451 | Terminal phase elimination half-life in healthy human at 1000 mg/kg, po administered single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571837 | Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 32 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495454 | Terminal volume of distribution in healthy human at 50 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571840 | Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495536 | Toxicity in human assessed as occurrence of diarrhea at 750 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID571145 | Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571144 | Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495546 | Cmax in human at 250 mg/kg, po measured on day 1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID570666 | Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus by CLSI M7-A7 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571875 | Antibacterial activity against Acinetobacter baumannii assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495534 | Toxicity in human assessed as occurrence of diarrhea at 250 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID570680 | Ratio of fAUC (0 to 24 hrs) in in vitro PK/PD model at 750 mg to MIC for Streptococcus pneumoniae | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495542 | Toxicity in human assessed as occurrence of somnolence at 500 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID571835 | Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495418 | Toxicity in healthy human assessed as occurrence of ear pain at 25 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495492 | Ratio of fAUC to MIC90 for ciprofloxacin-resistant Streptococcus pneumoniae | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571384 | Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495374 | Toxicity in healthy human assessed as occurrence of pruritus at 1000 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495457 | Terminal volume of distribution in healthy human at 500 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495462 | Clearance in healthy human at 125 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495376 | Toxicity in healthy human assessed as occurrence of erythema at 25 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571375 | Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 32 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571846 | Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495370 | Toxicity in healthy human assessed as occurrence of pruritus at 50 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495446 | Terminal phase elimination half-life in healthy human at 25 mg/kg, po administered single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495580 | Terminal half life in human at 1000 mg/kg, po measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID570686 | Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495491 | Ratio of fAUC to MIC90 for penicillin-resistant Streptococcus pneumoniae | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571349 | Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.03 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571367 | Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID570930 | Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495618 | AUC (0 to last) in human at 750 mg/kg, po measured on day 1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID571151 | Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 128 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495524 | Toxicity in human assessed as occurrence of rashes at 250 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID570709 | Antibacterial activity against Levofloxacin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of <=0.008 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571350 | Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495522 | Toxicity in human assessed as occurrence of dermatitis at 750 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495597 | Oral clearance in human at 500 mg/kg measured on day 1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495464 | Clearance in healthy human at 500 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495373 | Toxicity in healthy human assessed as occurrence of pruritus at 500 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495406 | Toxicity in healthy human assessed as occurrence of pustular rashes at 125 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495466 | Clearance in healthy human at 1500 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571865 | Antibacterial activity against Stenotrophomonas maltophilia assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495525 | Toxicity in human assessed as occurrence of rashes at 1000 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID571376 | Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 64 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495568 | Tmax in human at 1000 mg/kg, po measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495423 | Toxicity in healthy human assessed as occurrence of ear pain at 1000 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495397 | Toxicity in healthy human assessed as occurrence of abdominal pain at 25 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571871 | Antibacterial activity against Stenotrophomonas maltophilia assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495443 | Tmax in healthy human at 500 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571876 | Antibacterial activity against Acinetobacter baumannii assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571374 | Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571140 | Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.03 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571372 | Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495485 | Antimicrobial activity against ciprofloxacin-resistant Streptococcus pneumoniae | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495579 | Terminal half life in human at 500 mg/kg, po measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495540 | Toxicity in human assessed as occurrence of pollakiuria at 500 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID571354 | Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495490 | Ratio of fAUC to MIC90 for penicillin-intermediate Streptococcus pneumoniae | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571362 | Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 256 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495415 | Toxicity in healthy human assessed as occurrence of nausea at 500 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495377 | Toxicity in healthy human assessed as occurrence of erythema at 50 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID570888 | Antibacterial activity against Levofloxacin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.03 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495565 | Tmax in human at 750 mg/kg, po measured on day 1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID571368 | Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571383 | Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495404 | Toxicity in healthy human assessed as occurrence of pustular rashes at 25 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495550 | Cmax in human at 500 mg/kg, po measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495487 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571851 | Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495382 | Toxicity in healthy human assessed as occurrence of erythema at 1500 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495564 | Tmax in human at 500 mg/kg, po measured on day 16 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495486 | Antimicrobial activity against methicillin-sensitive Staphylococcus aureus | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495453 | Terminal volume of distribution in healthy human at 25 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571379 | Antibacterial activity against Klebsiella oxytoca assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495590 | Clearance in human assessed as compound recovered in urine at 750 mg/kg, po measured on day 10 up to 24 hrs post dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495519 | Toxicity in human assessed as incidence of headache at 1000 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495587 | Clearance in human assessed as compound recovered in urine at 500 mg/kg, po measured on day 10 up to 24 hrs post dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID570897 | Antibacterial activity against non-levofloxacin susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571355 | Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495620 | AUC (0 to last) in human at 1000 mg/kg, po measured on day 1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID570670 | Antibacterial activity against penicillin-resistant Streptococcus pneumoniae by CLSI M7-A7 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495561 | Tmax in human at 250 mg/kg, po measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495430 | AUC (0 to infinity) in healthy human at 1000 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495392 | Toxicity in healthy human assessed as occurrence of oral hypoesthesia at 125 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495448 | Terminal phase elimination half-life in healthy human at 125 mg/kg, po administered single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571854 | Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID570669 | Antibacterial activity against Streptococcus pneumoniae by CLSI M7-A7 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495414 | Toxicity in healthy human assessed as occurrence of nausea at 250 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495520 | Toxicity in human assessed as occurrence of dermatitis at 250 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495390 | Toxicity in healthy human assessed as occurrence of oral hypoesthesia at 25 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571109 | Antibacterial activity against methicillin-resistant Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495547 | Cmax in human at 500 mg/kg, po measured on day 1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495467 | Renal clearance in healthy human at 25 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571346 | Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 64 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495552 | Cmax in human at 750 mg/kg, po measured on day 1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID570673 | Antibacterial activity against Enterobacteriaceae by CLSI M7-A7 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571147 | Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495558 | Tmax in human at 75 mg/kg, po measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID570677 | Ratio of fAUC (0 to 24 hrs) in in vitro PK/PD model at 750 mg to MIC for Staphylococcus aureus | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495470 | Renal clearance in healthy human at 250 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571146 | Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495541 | Toxicity in human assessed as occurrence of somnolence at 250 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID570691 | Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571861 | Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 256 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495479 | Clearance in healthy human assessed as recovery of unchanged drug in urine at 1000 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571378 | Antibacterial activity against Klebsiella oxytoca assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495606 | Renal clearance in human at 500 mg/kg, po measured on day 1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID571352 | Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571112 | Antibacterial activity against methicillin-resistant Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID570704 | Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID570695 | Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 64 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495447 | Terminal phase elimination half-life in healthy human at 50 mg/kg, po administered single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495379 | Toxicity in healthy human assessed as occurrence of erythema at 250 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID570889 | Antibacterial activity against Levofloxacin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495592 | Clearance in human assessed as compound recovered in urine at 1000mg/kg, po measured on day 10 up to 24 hrs post dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495496 | Ratio of fCmax to MIC90 for penicillin-sensitive Streptococcus pneumoniae | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495411 | Toxicity in healthy human assessed as occurrence of nausea at 25 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571857 | Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495407 | Toxicity in healthy human assessed as occurrence of pustular rashes at 250 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495554 | Cmax in human at 1000 mg/kg, po measured on day 1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID570682 | Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of <=0.008 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495381 | Toxicity in healthy human assessed as occurrence of erythema at 1000 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571868 | Antibacterial activity against Stenotrophomonas maltophilia assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID570922 | Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495608 | Renal clearance in human at 500 mg/kg, po measured on day 16 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495548 | Cmax in human at 250 mg/kg, po measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID571856 | Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495531 | Toxicity in human assessed as occurrence of pruritus at 250 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495477 | Clearance in healthy human assessed as recovery of unchanged drug in urine at 250 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571873 | Antibacterial activity against Stenotrophomonas maltophilia assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 64 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495475 | Clearance in healthy human assessed as recovery of unchanged drug in urine at 50 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495402 | Toxicity in healthy human assessed as occurrence of abdominal pain at 1000 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495616 | AUC (0 to last) in human at 250 mg/kg, po measured on day 1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495593 | Oral clearance in human at 75 mg/kg measured on day 1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495372 | Toxicity in healthy human assessed as occurrence of pruritus at 250 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495459 | Terminal volume of distribution in healthy human at 1500 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID570902 | Antibacterial activity against non-levofloxacin susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID570674 | Antibacterial activity against Pseudomonas aeruginosa by CLSI M7-A7 broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID570692 | Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495412 | Toxicity in healthy human assessed as occurrence of nausea at 50 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571142 | Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571369 | Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495461 | Clearance in healthy human at 50 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID570679 | Ratio of fAUC (0 to 24 hrs) in in vitro PK/PD model at 750 mg to MIC for Staphylococcus epidermidis | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495438 | Cmax in healthy human at 1500 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID570919 | Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID570931 | Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495626 | Oral clearance in human at 750 mg/kg measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495527 | Toxicity in human assessed as occurrence of abdominal pain at 500 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID571364 | Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of <=0.015 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495368 | Toxicity in healthy human assessed as occurrence of contact dermatitis at 1500 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495363 | Toxicity in healthy human assessed as occurrence of contact dermatitis at 250 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID570681 | Ratio of fAUC (0 to 24 hrs) in in vitro PK/PD model at 750 mg to MIC for penicillin-resistant Streptococcus pneumoniae | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID570698 | Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495549 | Cmax in human at 75 mg/kg, po measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID571855 | Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571341 | Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495385 | Toxicity in healthy human assessed as occurrence of headache at 125 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID570678 | Ratio of fAUC (0 to 24 hrs) in in vitro PK/PD model at 750 mg to MIC for community-associated methicillin-resistant Staphylococcus aureus | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571119 | Antibacterial activity against Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.03 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID570908 | Antibacterial activity against community-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID570693 | Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495445 | Tmax in healthy human at 1500 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495478 | Clearance in healthy human assessed as recovery of unchanged drug in urine at 500 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571104 | Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571373 | Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495365 | Toxicity in healthy human assessed as occurrence of contact dermatitis at 50 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495609 | Renal clearance in human at 750 mg/kg, po measured on day 1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID571858 | Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 32 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495581 | Terminal half life in human at 250 mg/kg, po measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495595 | Oral clearance in human at 250 mg/kg measured on day 1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495560 | AUC (0 to last) in human at 500 mg/kg, po measured on day 16 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID570915 | Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.015 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571110 | Antibacterial activity against methicillin-resistant Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495571 | AUC (0 to 24 hrs) in human at 250 mg/kg, po measured on day 1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID571131 | Antibacterial activity against penicillin-resistant Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.03 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495493 | Ratio of fAUC to MIC90 for methicillin-sensitive Staphylococcus aureus | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495456 | Terminal volume of distribution in healthy human at 250 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495409 | Toxicity in healthy human assessed as occurrence of pustular rashes at 1000 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495391 | Toxicity in healthy human assessed as occurrence of oral hypoesthesia at 50 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID570703 | Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571386 | Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495484 | Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571387 | Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID570890 | Antibacterial activity against Levofloxacin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571337 | Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495452 | Terminal phase elimination half-life in healthy human at 1500 mg/kg, po administered single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571859 | Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 64 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495369 | Toxicity in healthy human assessed as occurrence of pruritus at 25 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495416 | Toxicity in healthy human assessed as occurrence of nausea at 1000 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495624 | AUC (0 to last) in human at 500 mg/kg, po measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495582 | Clearance in human assessed as compound recovered in urine at 75 mg/kg, po measured on day 1 up to 24 hrs post dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495362 | Toxicity in healthy human assessed as occurrence of contact dermatitis at 500 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID571132 | Antibacterial activity against penicillin-resistant Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495539 | Toxicity in human assessed as occurrence of pollakiuria at 250 mg/kg, po administered as single dose | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID571117 | Antibacterial activity against Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of <=0.008 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495628 | Ratio of fAUC (0 to 24 hrs) to MIC90 for Streptococcus pneumoniae | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID571360 | Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 64 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID570911 | Antibacterial activity against community-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID570903 | Antibacterial activity against non-levofloxacin susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 32 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571143 | Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495622 | AUC (0 to 24 hrs) in human at 500 mg/kg, po measured on day 16 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID571377 | Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 128 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571122 | Antibacterial activity against Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495613 | AUC (0 to 24 hrs) in human at 75 mg/kg, po measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID571371 | Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID495384 | Toxicity in healthy human assessed as occurrence of headache at 50 mg/kg, po | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. |
AID495545 | Cmax in human at 75 mg/kg, po measured on day 1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495563 | Tmax in human at 500 mg/kg, po measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID495555 | Cmax in human at 1000 mg/kg, po measured on day 10 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. |
AID571336 | Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571356 | Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571877 | Antibacterial activity against Acinetobacter baumannii assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
AID571344 | Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (7.69) | 29.6817 |
2010's | 30 (76.92) | 24.3611 |
2020's | 6 (15.38) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (40.91) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 15 (37.50%) | 5.53% |
Reviews | 4 (10.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 1 (2.50%) | 0.25% |
Other | 20 (50.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Multi-center, Randomized, Double-Blind, Parallel Comparative, Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin Versus Levofloxain in Treating Adult Patients With CAP [NCT02205112] | Phase 3 | 598 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
A Randomized, Single-center, Placebo and Positive Control, 4-period and 4-crossover Clinical Study Evaluating the Effect of a Single-dose Oral Administration of Nemonoxacin Malate Capsule on QTc Intervals and Heart Rhythms of Healthy Subjects as Well as t [NCT03362853] | Phase 1 | 48 participants (Actual) | Interventional | 2012-06-25 | Completed | ||
A Multi-Center, Open-Label, Single-Arm, Phase IV Study to Evaluate the Safety and Clinical Efficacy of Oral Administration With Nemonoxacin in Treating Elderly Patients With Community-Acquired Pneumonia [NCT05133752] | Phase 4 | 100 participants (Actual) | Interventional | 2018-09-11 | Completed | ||
Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Moderate Impaired Hepatic Function [NCT02604498] | Phase 1 | 20 participants (Actual) | Interventional | 2016-04-14 | Completed | ||
Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Severe Impaired Renal Function [NCT02840812] | Phase 1 | 24 participants (Anticipated) | Interventional | 2017-04-05 | Recruiting | ||
An Open-Label, Single-Arm, Multi-Center Study of TG-873870 for Treating Patients With Diabetic Foot Infections of Mild to Moderate Severity Associated With Gram-Positive Pathogens [NCT00685698] | Phase 2 | 40 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
Phase I Clinical Study on Oral Nemonoxacin Malate Capsules [NCT01395108] | Phase 1 | 76 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
A Randomized, Double-Blind, Comparative, Multi-Center Study of the Safety and Efficacy of TG-873870(Nemonoxacin) Versus Levofloxacin in Adult Patients With Community-Acquired Pneumonia (CAP) [NCT00434291] | Phase 2 | 264 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
A Randomized, Double-Blind, Comparative, Multi-Center Study of the Safety and Efficacy of TG-873870(Nemonoxacin) Versus Levofloxacin in Adult Patients With Community-Acquired Pneumonia (CAP) [NCT01529476] | Phase 3 | 540 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
A Phase I Clinical Study of Nemonoxacin Malate Sodium Chloride Injection Administered by Intravenous Infusion [NCT01529957] | Phase 1 | 176 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
A Multi-center, Randomized, Double-blind, Double-dummy Parallel-controlled Phase II Clinical Study to Assess the Efficacy and Safety of Nemonoxacin Malate in Treating Adult Patients With Community-acquired Pneumonia (CAP) [NCT01537250] | Phase 2 | 192 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
A Multi-Center, Randomized, Double-Blind, Parallel Comparative, Phase II Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Versus Moxifloxacin in Treating Adult Patients With Community-Acquired Pneumonia (CAP) [NCT01944774] | Phase 2 | 207 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
An International, Multicenter, Randomized, Double-blind, Double-dummy, Two-way, Parallel Group, Controlled Study to Compare the Efficacy and Safety of Intravenous and Oral Nemonoxacin Versus Tavanic® in Adult Patients With Community-acquired Pneumonia [NCT03551210] | Phase 3 | 342 participants (Actual) | Interventional | 2016-05-04 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |